Refine
Year of publication
Document Type
- Article (218)
- Preprint (92)
- Conference Proceeding (4)
- Book (2)
- Review (2)
Language
- English (303)
- German (14)
- Multiple languages (1)
Has Fulltext
- yes (318)
Is part of the Bibliography
- no (318)
Keywords
- BESIII (9)
- Branching fraction (7)
- e +-e − Experiments (7)
- Lepton colliders (4)
- Particle and Resonance Production (4)
- Charm Physics (3)
- Charmed mesons (3)
- Electroweak interaction (3)
- Hadronic decays (3)
- e+-e− Experiments (3)
- Biomarkers (2)
- Branching fractions (2)
- CV9202 (2)
- Charm physics (2)
- Consensus (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Exotics (2)
- Früherkennung (2)
- Leptonic, semileptonic & radiative decays (2)
- MRI (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Particle decays (2)
- Polarization (2)
- Quarkonium (2)
- Rehabilitation (2)
- Richtlinie (2)
- SARS-CoV-2 (2)
- Spectroscopy (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- ACL (1)
- ATM (1)
- Actin (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute inflammation (1)
- Acute myeloid leukemia (1)
- Alzheimer's disease (1)
- Animal models (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Archaeogeophysics (1)
- Ascites (1)
- Auditory system (1)
- Austria (1)
- Automata theory (1)
- B cell receptor (1)
- BESIII detector (1)
- BI1361849 (1)
- BPDCN (1)
- Berci needle (1)
- Bevacizumab (1)
- Bhabha (1)
- Bone conduction devices (1)
- Born cross section measurement (1)
- BrainNet Europe consortium (1)
- Business strategy in drug development (1)
- Bypass liner (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- CAKUT (1)
- CDKN2A (1)
- COVID-19 (1)
- CP violation (1)
- CRISPR/Cas (1)
- Cancer (1)
- Capecitabine (1)
- Cardiomyopathy (1)
- Carex firma community (1)
- Carex sempervirens community (1)
- Caricion davallianae (1)
- Charmonia (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Cherenkov counter: lead-glass (1)
- Child (1)
- Chondral Lesion (1)
- Cirrhosis (1)
- Claudin 5 (1)
- Clinical trial (1)
- Cognitive impairment (1)
- Cohort studies (1)
- Comparative effectiveness research (1)
- Complex I (1)
- Consensus statement (1)
- Covid-19 (1)
- Cross section (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- Dermatomyositis (1)
- Diabetes (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Diagnostic markers (1)
- Dilated cardiomyopathy (1)
- Direct oral anticoagulation (1)
- Drug screens (1)
- Drug therapy (1)
- Dumon stents (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Endoscopy (1)
- Esophageal adenocarcinoma (1)
- Exercise (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FAPI PET (1)
- FOS: Physical sciences (1)
- Fagus sylvatica (1)
- Festuco-Brometea (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Full waveform (1)
- Function (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Genome editing (1)
- Glioblastoma survival (1)
- HADES (1)
- HIV (1)
- HIV-1 (1)
- Haploidentical stem cell transplantation (1)
- Harz Mountains foothills (1)
- Health policy (1)
- Heart (1)
- Heart transplantation (1)
- Heavy ion storage ring (1)
- Hematology (1)
- Hepatitis C virus (1)
- Hereditary angioedema (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hsp70 (1)
- Hyperons (1)
- Hypofractionated radiotherapy (1)
- IHC (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Initial state radiation (1)
- Interpretation (1)
- Intragastric balloon (1)
- Inversion (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- KIR (1)
- KRAS (1)
- Lactic acidosis (1)
- Leukemias (1)
- Liver diseases (1)
- Liver transplantation (1)
- Low-molecular-weight heparin (1)
- MEDIC (1)
- MLL (1)
- Mena/VASP (1)
- Minimal residual disease (1)
- Mitochondrial disorder (1)
- Mixed hearing loss (1)
- Molecular diagnostic testing (1)
- Molinio-Arrhenatheretea (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- NK cells (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NRAS (1)
- Neonatal (1)
- Neural network (1)
- Neutrinos (1)
- Noninferiority (1)
- Obesity (1)
- Orbital electron capture (1)
- Ovarian cancer (1)
- Oxaliplatin (1)
- PDE‐5‐inhibitor (1)
- Parkinson disease (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Patellofemoral Joint (1)
- Pediatric (1)
- Physiotherapy (1)
- Preoperative radiochemotherapy (1)
- Prognosis (1)
- Proton (1)
- Pulmonary embolism (1)
- QCD (1)
- Quantum chromodynamics (1)
- RHIC (1)
- RNActive (1)
- Radiative decay (1)
- Rare decays (1)
- Rectal cancer (1)
- Registries (1)
- Renal lesions (1)
- Renal replacement therapy (1)
- Respiration (1)
- SCCHN (1)
- SLC20A1 (1)
- STAR (1)
- STIR (1)
- Semi-leptonic decays (1)
- Single particle decay spectroscopy (1)
- Single-leg hop for distance (1)
- Spectrin (1)
- Spin alignment (1)
- Surgery (1)
- TILs (1)
- TLR2/6 (1)
- TR (1)
- Technical data (1)
- Techniques Electromagnetic calorimeters (1)
- Therapeutic anticoagulation (1)
- Tomography (1)
- Tracking (1)
- Transition radiation detector (1)
- Treatment (1)
- Trigger (1)
- Two body weak decay (1)
- VE-cadherin (1)
- VEGF (1)
- VISTA (1)
- Validity (1)
- Vascular permeability (1)
- Violion caninae (1)
- Vitamin (1)
- Weight loss (1)
- Xenon-based gas mixture (1)
- Y states (1)
- acute myeloid leukemia (1)
- adult and elderly patients (1)
- aegean (1)
- airway (1)
- algorithms (1)
- alpine vegetation (1)
- angiogenesis (1)
- annual bleeding rate (1)
- arteriogenesis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory system (1)
- beech forests (1)
- bladder exstrophy-epispadias complex (1)
- blastic plasmacytoid dendritic cell neoplasm (1)
- blood flow recovery (1)
- bone-marrow (1)
- calorimeter: electromagnetic (1)
- center-of-mass energy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- charmonium-like states (1)
- cisplatin (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- cohlear implant (1)
- collateral growth (1)
- combinatorics (1)
- comorbidity (1)
- component study (1)
- cone-beam computed tomography (CBCT) (1)
- cone-beam computer tomography (1)
- coronary artery disease (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- data structures (1)
- decompressive craniectomy (1)
- denervation (1)
- dimuon (1)
- dynamic vegetation model (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- early tumor stages (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- electron-positron collision (1)
- electronics: readout (1)
- endothelial function (1)
- erectile dysfunction (1)
- femoral artery ligation (1)
- fibre: optical (1)
- fibrosis imaging (1)
- fluid shear stress (1)
- foraminifera (1)
- functional genetics (1)
- geophysical prospections (1)
- global warming (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- hearing loss (1)
- helicity amplitude analysis (1)
- hierarchies and reducibilities (1)
- immunohistochemistry (1)
- inclusive J/ψ decays (1)
- inner ear (1)
- intracerebral hemorrhage (ICH) (1)
- intratumoral (1)
- kidney formation (1)
- lipiodol (1)
- local radiotherapy (1)
- logic (1)
- lung cancer (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- magnetic gradiometry (1)
- micropalaeontology (1)
- microwave ablation (1)
- mindfulness (1)
- monocytes (1)
- multicenter study (1)
- mutually exclusive mutations (1)
- mycorrhiza (1)
- nanoparticle (1)
- natural reforestation (1)
- neurofibrillary pathology (1)
- neuropathological diagnosis (1)
- neutralizing antibodies (1)
- next generation sequencing (1)
- nitrogen deposition (1)
- non-small cell lung cancer (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- nutrient cycling (1)
- permanent plots (1)
- plant community assembly (1)
- plant functional traits (1)
- plant succession (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- portal hypertension (1)
- prognosis (1)
- prognostic biomarker (1)
- psychotherapy process (1)
- pulmonary hypertension (1)
- radiation (1)
- randomized controlled trial (RCT) (1)
- reactive systems (1)
- recurrent mutations (1)
- retrospective trial (1)
- rolipram (1)
- solitary pulmonary nodule (1)
- species composition (1)
- species richness (1)
- specification and verification (1)
- spike protein (1)
- spiral ganglion cell (1)
- stability (1)
- stent (1)
- succession (1)
- tetraquark (1)
- therapeutic alliance (1)
- tracheobronchomalacia (1)
- transbronchial biopsy (TBB) (1)
- trigger efficiency (1)
- tropical montane forests (TMF) (1)
- urinary tract development (1)
- vaccination (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- variants of concern (1)
- vegetation classification (1)
- verification (1)
- von Willebrand disease (1)
- windthrow (1)
- zebrafish development (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Institute
Dieses Papier präsentiert erste Ergebnisse der bundesweiten Studie JuCo – Erfahrungen und Perspektiven von jungen Menschen während der Corona-Maßnahmen. Die Befragung wurde vom Forschungsverbund "Kindheit – Jugend – Familie in der Corona-Zeit" umgesetzt, der sich aus den Universitäten Hildesheim, Frankfurt und Bielefeld zusammensetzt. Über 5.000 Jugendliche und junge Erwachsene zwischen 15 und 30 Jahren sind in die Analysen eingeflossen und zeigen auf, wie es den jungen Menschen geht und welche Botschaften sie haben.
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.
Profiles of CFC-11 (CCl3F) and CFC-12 (CCl2F2) of the Michelson Interferometer for Passive Atmospheric Sounding (MIPAS) aboard the European satellite Envisat have been retrieved from versions MIPAS/4.61 to MIPAS/4.62 and MIPAS/5.02 to MIPAS/5.06 level-1b data using the scientific level-2 processor run by Karlsruhe Institute of Technology (KIT), Institute of Meteorology and Climate Research (IMK) and Consejo Superior de Investigaciones Científicas (CSIC), Instituto de Astrofísica de Andalucía (IAA). These profiles have been compared to measurements taken by the balloon-borne cryosampler, Mark IV (MkIV) and MIPAS-Balloon (MIPAS-B), the airborne MIPAS-STRatospheric aircraft (MIPAS-STR), the satellite-borne Atmospheric Chemistry Experiment Fourier transform spectrometer (ACE-FTS) and the High Resolution Dynamic Limb Sounder (HIRDLS), as well as the ground-based Halocarbon and other Atmospheric Trace Species (HATS) network for the reduced spectral resolution period (RR: January 2005–April 2012) of MIPAS. ACE-FTS, MkIV and HATS also provide measurements during the high spectral resolution period (full resolution, FR: July 2002–March 2004) and were used to validate MIPAS CFC-11 and CFC-12 products during that time, as well as profiles from the Improved Limb Atmospheric Spectrometer, ILAS-II. In general, we find that MIPAS shows slightly higher values for CFC-11 at the lower end of the profiles (below ∼ 15 km) and in a comparison of HATS ground-based data and MIPAS measurements at 3 km below the tropopause. Differences range from approximately 10 to 50 pptv ( ∼ 5–20 %) during the RR period. In general, differences are slightly smaller for the FR period. An indication of a slight high bias at the lower end of the profile exists for CFC-12 as well, but this bias is far less pronounced than for CFC-11 and is not as obvious in the relative differences between MIPAS and any of the comparison instruments. Differences at the lower end of the profile (below ∼ 15 km) and in the comparison of HATS and MIPAS measurements taken at 3 km below the tropopause mainly stay within 10–50 pptv (corresponding to ∼ 2–10 % for CFC-12) for the RR and the FR period. Between ∼ 15 and 30 km, most comparisons agree within 10–20 pptv (10–20 %), apart from ILAS-II, which shows large differences above ∼ 17 km. Overall, relative differences are usually smaller for CFC-12 than for CFC-11. For both species – CFC-11 and CFC-12 – we find that differences at the lower end of the profile tend to be larger at higher latitudes than in tropical and subtropical regions. In addition, MIPAS profiles have a maximum in their mixing ratio around the tropopause, which is most obvious in tropical mean profiles. Comparisons of the standard deviation in a quiescent atmosphere (polar summer) show that only the CFC-12 FR error budget can fully explain the observed variability, while for the other products (CFC-11 FR and RR and CFC-12 RR) only two-thirds to three-quarters can be explained. Investigations regarding the temporal stability show very small negative drifts in MIPAS CFC-11 measurements. These instrument drifts vary between ∼ 1 and 3 % decade−1. For CFC-12, the drifts are also negative and close to zero up to ∼ 30 km. Above that altitude, larger drifts of up to ∼ 50 % decade−1 appear which are negative up to ∼ 35 km and positive, but of a similar magnitude, above.
The three-dimensional quantification of small scale processes in the upper troposphere and lower stratosphere is one of the challenges of current atmospheric research and requires the development of new measurement strategies. This work presents first results from the newly developed Gimballed Limb Observer for Radiance Imaging of the Atmosphere (GLORIA) obtained during the ESSenCe and TACTS/ESMVal aircraft campaigns. The focus of this work is on the so-called dynamics mode data characterized by a medium spectral and a very high spatial resolution. The retrieval strategy for the derivation of two- and three-dimensional constituent fields in the upper troposphere and lower stratosphere is presented. Uncertainties of the main retrieval targets (temperature, O3, HNO3 and CFC-12) and their spatial resolution are discussed. During ESSenCe, high resolution two-dimensional cross-sections have been obtained. Comparisons to collocated remote-sensing and in-situ data indicate a good agreement between the data sets. During TACTS/ESMVal a tomographic flight pattern to sense an intrusion of stratospheric air deep into the troposphere has been performed. This filament could be reconstructed with an unprecedented spatial resolution of better than 500 m vertically and 20 km × 20 km horizontally.
The three-dimensional quantification of small-scale processes in the upper troposphere and lower stratosphere is one of the challenges of current atmospheric research and requires the development of new measurement strategies. This work presents the first results from the newly developed Gimballed Limb Observer for Radiance Imaging of the Atmosphere (GLORIA) obtained during the ESSenCe (ESa Sounder Campaign) and TACTS/ESMVal (TACTS: Transport and composition in the upper troposphere/lowermost stratosphere, ESMVal: Earth System Model Validation) aircraft campaigns. The focus of this work is on the so-called dynamics-mode data characterized by a medium-spectral and a very-high-spatial resolution. The retrieval strategy for the derivation of two- and three-dimensional constituent fields in the upper troposphere and lower stratosphere is presented. Uncertainties of the main retrieval targets (temperature, O3, HNO3, and CFC-12) and their spatial resolution are discussed. During ESSenCe, high-resolution two-dimensional cross-sections have been obtained. Comparisons to collocated remote-sensing and in situ data indicate a good agreement between the data sets. During TACTS/ESMVal, a tomographic flight pattern to sense an intrusion of stratospheric air deep into the troposphere was performed. It was possible to reconstruct this filament at an unprecedented spatial resolution of better than 500 m vertically and 20 × 20 km horizontally.
Creatinine and proteinuria are used to monitor kidney transplant patients. However, renal biopsies are needed to diagnose renal graft rejection. Here, we assessed whether the quantification of different urinary cells would allow non-invasive detection of rejection. Urinary cell numbers of CD4+ and CD8+ T cells, monocytes/macrophages, tubular epithelial cells (TEC), and podocalyxin(PDX)-positive cells were determined using flow cytometry and were compared to biopsy results. Urine samples of 63 renal transplant patients were analyzed. Patients with transplant rejection had higher amounts of urinary T cells than controls; however, patients who showed worsening graft function without rejection had similar numbers of T cells. T cells correlated with histological findings (interstitial inflammation p = 0.0005, r = 0.70; tubulitis p = 0.006, r = 0.58). Combining the amount of urinary T cells and TEC, or T cells and PDX+ cells, yielded a significant segregation of patients with rejection from patients without rejection (all p < 0.01, area under the curve 0.89–0.91). Urinary cell populations analyzed by flow cytometry have the potential to introduce new monitoring methods for kidney transplant patients. The combination of urinary T cells, TEC, and PDX-positive cells may allow non-invasive detection of transplant rejection.
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with <nCR after first ASCT were assigned tandem ASCT in both trials. In patients with <nCR and tandem ASCT (LEN: n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.
Background The role of the Fcgamma receptor IIa (FcgammaRIIa), a receptor for C-reactive protein (CRP), the classical acute phase protein, in atherosclerosis is not yet clear. We sought to investigate the association of FcgammaRIIa genotype with risk of coronary heart disease (CHD) in two large population-based samples. Methods FcgammaRIIa-R/H131 polymorphisms were determined in a population of 527 patients with a history of myocardial infarction and 527 age and gender matched controls drawn from a population-based MONICA- Augsburg survey. In the LURIC population, 2227 patients with angiographically proven CHD, defined as having at least one stenosis [greater than or equal to]50%, were compared with 1032 individuals with stenosis <50%. Results In both populations genotype frequencies of the FcgammaRIIa gene did not show a significant departure from the Hardy-Weinberg equilibrium. FcgammaRIIa R(-131)->H genotype was not independently associated with lower risk of CHD after multivariable adjustments, neither in the MONICA population (odds ratio (OR) 1.08; 95% confidence interval (CI) 0.81 to 1.44), nor in LURIC (OR 0.96; 95% CI 0.81 to 1.14). Conclusion Our results do not confirm an independent relationship between FcgammaRIIa genotypes and risk of CHD in these populations.
Introduction: Prophylaxis with factor VIII (FVIII) concentrates in children with haemophilia A (HA) is current standard of care. The benefit of prophylactic treatment for adult HA patients is not commonly accepted.
Aim: To investigate the benefit of prophylaxis over on‐demand treatment in adult and elderly patients with severe or non‐severe HA in a real‐life setting.
Methods: Data from 163 patients comprising 1202 patient‐years were evaluated for 7.5 (±5.3) years. The effects on the annual bleeding rate (ABR, including spontaneous and traumatic bleeds) of treatment with a plasma‐derived FVIII concentrate, the patient's age and disease severity were investigated. The effect of changing the treatment from on demand to continuous prophylaxis on the patients’ ABRs was further analysed.
Results: Prophylaxis had the greatest effect on the ABRs of patients of any age with severe or non‐severe HA. The difference in ABR of all patients treated on demand (median 31.4; interquartile range (IQR) 27.6; N = 83) compared with those treated prophylactically (median 1.3; IQR 3.6; N = 122) was statistically significant (P < .05), even for patients with non‐severe HA (median 8.4; IQR 15.5; N = 11) vs median 1.5; IQR 4.2 (N = 17), P < .05). Patients, aged up to 88 years, switching from on demand to continuous prophylaxis showed the lowest median ABR (1.1; N = 51) after their regimen change.
Conclusion: Any (even low‐frequency) prophylaxis results in lower ABR than on‐demand treatment. Patients switching to prophylaxis benefitted the most, irrespective of age or HA severity. Prophylactic treatment—even tertiary—is the regimen of choice for patients of any age, including elderly patients, with severe or non‐severe HA.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.